ATLANTA, March 4, 2020 /PRNewswire/ -- CryoLife, Inc.
(NYSE: CRY), a leading cardiac and vascular surgery company
focused on aortic disease, announced today that it has received CE
Mark for the E-vita Open NEO, a
hybrid stent graft system for the treatment of aortic arch
disease.
Aortic arch disease includes both aortic aneurysms and aortic
dissections, which occur suddenly and usually without warning.
Approximately 7,000 patients are surgically treated for thoracic
aortic arch disease annually in Europe, the Middle
East and Africa. Many patients with either an aneurysm
or dissection in the aortic arch also present with a dissected or
aneurysmal descending thoracic aorta. Often these two
conditions are repaired in a two-stage procedure – one to repair
the arch and the next to repair the descending thoracic
aorta. The Company's hybrid stent graft technologies, which
include the E-vita Open NEO and the E-vita Open Plus, enable a
one-stage procedure treatment of this condition by combining the
surgical arch repair and the endovascular descending thoracic
repair, providing a more cost effective solution for the health
system and allowing the patient to avoid a second surgery. It
is anticipated that the E-vita Open NEO often will be used in
combination with JOTEC's thoracic stent graft offering, E-nya.
"We are pleased to have received CE Mark for E-vita Open NEO,
our newest hybrid stent graft technology for aortic arch and
descending thoracic aorta repair. This new design features a
single tri-branched vessel that enhances ease-of-use and
implantation that reduces surgical time and allows for a
potentially safer procedure, thereby increasing the likelihood that
more patients can benefit from the procedure and patient access to
these therapies," remarked Pat
Mackin, Chairman, President, and Chief Executive Officer of
CryoLife.
PD. Dr. med. Konstantinos
Tsagakis and Prof. Dr. med. Arjang Ruhparwar in Essen, Germany commented, "15 years ago, the
introduction of the Evita Open Plus hybrid stent graft changed
conventional open aortic arch surgery. The device concept is
simple - it combines the open surgical approach for the arch with
an endovascular treatment of the descending thoracic aorta.
In our 350 patient experience in Essen, the ability of this device to address
the major challenge of this surgery has translated into better
outcomes for the patient, including an improved 5-year survival
rate. CryoLife's next generation hybrid stent graft, the
E-vita Open NEO, will continue
to advance this procedure by providing surgeons with more options
for treating the most complex patient anatomies in a safe and
reproducible manner."
About CryoLife
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the
manufacturing, processing, and distribution of medical devices and
implantable tissues used in cardiac and vascular surgical
procedures focused on aortic repair. CryoLife markets and
sells products in more than 100 countries worldwide. For
additional information about CryoLife, visit our website,
www.cryolife.com.
Contacts:
CryoLife
|
Gilmartin Group
LLC
|
D. Ashley
Lee
|
Greg Chodaczek / Lynn
Lewis
|
Executive Vice
President, Chief Financial Officer and
Chief Operating Officer
|
Phone:
646-924-1769
investors@cryolife.com
|
Phone:
770-419-3355
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cryolife-receives-ce-mark-for-e-vita-open-neo-hybrid-stent-graft-301016645.html
SOURCE CryoLife, Inc.